Productivity, Sample quality and Integrity

AGM Presentation
AGM Presentation
Melbourne, Nov 26, 2018 AEST (ABN Newswire) - Bluechiip Ltd (ASX:BCT) provides the Company's AGM Presentation.

Highlights

- World first, highly differentiated technology, with protected IP

- >$200M growing target market, very large adjacent markets

- Dramatically increasing partner pipeline, 29 readers sold, up from 14 FY17

- Well advanced product development

- Partner opportunity conversion with three executed licence and supply agreements and Bluechiip Enabled products in manufacture

- Growing partner supply, over 250k chips delivered in 2H FY18.

- Initial repeat revenues with sales up 136% Y.O.Y

- Orders in hand with a three year supply agreement over $US11.6 million ($A15.9 million) with Labcon

- $7.5m Capital Raised in September 2018

To view the full presentation, please visit:
http://abnnewswire.net/lnk/TZ94T0VD


About Bluechiip Ltd

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at http://www.bluechiip.com

    


Contact

Andrew McLellan
Managing Director / CEO
Bluechiip Limited
T: +61-3-9763-9763
M: +61-457-823-470
Email: andrew.mclellan@bluechiip.com



Related Companies

Bluechiip Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 21) (Last 30 Days: 93) (Since Published: 662) 
ANALYTICS: LOGIN HERE

Bluechiip Ltd NEWS: RECENT VISITS (2598)

Research Report

Social Media